Fintel reports that on July 27, 2023, Wedbush reiterated coverage of Immunic (NASDAQ:IMUX) with a Outperform recommendation.
Analyst Price Forecast Suggests 850.00% Upside
As of July 6, 2023, the average one-year price target for Immunic is 19.38. The forecasts range from a low of 5.05 to a high of $36.75. The average price target represents an increase of 850.00% from its latest reported closing price of 2.04.
See our leaderboard of companies with the largest price target upside.
The projected annual revenue for Immunic is 0MM. The projected annual non-GAAP EPS is -2.15.
What is the Fund Sentiment?
There are 96 funds or institutions reporting positions in Immunic. This is a decrease of 5 owner(s) or 4.95% in the last quarter. Average portfolio weight of all funds dedicated to IMUX is 0.04%, an increase of 49.44%. Total shares owned by institutions decreased in the last three months by 1.32% to 25,071K shares. 
The put/call ratio of IMUX is 0.30, indicating a bullish outlook.
What are Other Shareholders Doing?
Rtw Investments holds 4,294K shares representing 9.67% ownership of the company. In it's prior filing, the firm reported owning 3,861K shares, representing an increase of 10.09%. The firm increased its portfolio allocation in IMUX by 20.75% over the last quarter.
Deep Track Capital holds 2,524K shares representing 5.68% ownership of the company.
Omega Fund Management holds 1,788K shares representing 4.03% ownership of the company. No change in the last quarter.
Gratus Capital holds 1,655K shares representing 3.73% ownership of the company. In it's prior filing, the firm reported owning 1,668K shares, representing a decrease of 0.78%. The firm increased its portfolio allocation in IMUX by 23.16% over the last quarter.
Artal Group holds 1,275K shares representing 2.87% ownership of the company. No change in the last quarter.
Immunic Background Information
(This description is provided by the company.)
Immunic, Inc. is a clinical-stage biopharmaceutical company with a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases, including relapsing-remitting multiple sclerosis, ulcerative colitis, Crohn's disease, and psoriasis. Immunic is developing three small molecule products: its lead development program, IMU-838, is a selective immune modulator that inhibits the intracellular metabolism of activated immune cells by blocking the enzyme DHODH and exhibits a host-based antiviral effect; IMU-935 is an inverse agonist of RORγt; and IMU-856 targets the restoration of the intestinal barrier function. Immunic announced positive results from its phase 2 EMPhASIS trial of IMU-838 in patients with relapsing-remitting multiple sclerosis, reporting achievement of both primary and key secondary endpoints with high statistical significance. IMU-838 is also in phase 2 clinical development for ulcerative colitis and COVID-19, with an additional phase 2 trial considered in Crohn's disease. An investigator-sponsored proof-of-concept clinical trial for IMU-838 in primary sclerosing cholangitis is ongoing at the Mayo Clinic.
Additional reading:
- Immunic, Inc. Reports First Quarter 2023 Financial Results and Provides Corporate Update – Positive Results From Phase 1b Clinical Trial of IMU-856 in Celiac Disease Provide Proof-of-Concept for a New Therapeutic Approach to Treat Gastrointestinal Di
- Immunic Reports Positive Results From Phase 1b Clinical Trial of IMU-856 in Celiac Disease, Providing Clinical Proof-of-Concept for New Therapeutic Approach to Gastrointestinal Disorders – Positive Effects Demonstrated Over Placebo in Four Key Dimens
- Presentation, dated May 4, 2023.
- Immunic, Inc. Strengthens Its Board of Directors with the Appointment of Richard Rudick, M.D. – Thought-Leader in Multiple Sclerosis with Decades of Experience in Academic Medicine and the Pharmaceutical Industry –
This story originally appeared on Fintel.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
